Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.I. Rapaport, L.V. Rao.
The tissue factor pathway : how it has become a “prima ballerina”.
Thromb Haemost, 74 (1995), pp. 7-17
[2.]
U. Hedner, W. Kisiel.
Use of human factor VII in the treatment of two hemophilia A patients with high-titer inhibitors.
J Clin Invest, 71 (1983), pp. 1836-1841
[3.]
U. Hedner, H. Kristensen, E. Berntorp, R. Ljung, P. Petrini, L. Tengborn.
Pharmacokinetics of rVIIa in children.
Haemophilia, 4 (1998), pp. 244
[4.]
U. Hedner, S. Glazer, K. Pingel, K.A. Alberts, M. Blomback, S. Schulman, et al.
Successful use of recombinant factor VIIa in patients with severe haemophilia during synovectomy.
The Lancet, ii (1988), pp. 1193
[5.]
J. Lusher, J. Ingerslev, H. Roberts, U. Hedner.
Clinical experience with recombinant factor VIIa.
Blood Coag Fibrinolysis, 9 (1998), pp. 119-128
[6.]
I. Scharrer.
Recombinant factor VIIa for patients with inhibitor to factor VIII or IX or factor VII deficiency.
Haemophilia, 5 (1999), pp. 253-259
[7.]
N.S. Key, L.M. Aledort, D. Beardsley, H.A. Cooper, G. Davignon, B.M. Ewenstein, et al.
Home treatment of mild to moderate episodes using recombinant factor VIIa (NovoSeven®) in haemophiliacs with inhibitor.
Throm Haemost, 80 (1998), pp. 912-918
[8.]
C.R.M. Hay, C. Negrier, C.A. Ludlam.
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
Thromb Haemost, 78 (1997), pp. 1463-1467
[9.]
J.M. Lusher, H.R. Roberts, G. Davignon, J.H. Joist, H. Smith, A. Shapiro, et al.
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. RVIIa Study group.
Haemophilia, 4 (1998), pp. 790-798
[10.]
G. Mariani, M.G. Testa, T. Di Paolantonio, B.R. Molskov, R. Bech, U. Hedner.
Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies.
Vox Sang, 77 (1999), pp. 131-136
[11.]
P. Girard, P. Nony, E. Ehardtsen, S. Delair, P. Ffrench, M. Dechavanne, et al.
Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocumarol.
Thromb Haemost, 80 (1998), pp. 109-113
[12.]
D.E. Bernstein, L. Jeffers, E. Erhardtsen, K.R. Reddy, S. Glazer, P. Squiban, et al.
Recombinat factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study.
Gastroenterology, 113 (1997), pp. 1930-1937
[13.]
J. Kristensen, A. Killander, E. Hippe, C. Helleberg, J. Ellegard, M. Holm, et al.
Clinical experience with recombinant factor VIIa in patients with thrombocytopenia.
Haemostasis, 26 (1996), pp. 159-164
[14.]
M.C. Poon, C. Demers, F. Jobin, J.W.Y. Wu.
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombastenia.
Blood, 94 (1999), pp. 3951-3953
[15.]
M. Peters, H. Heijboer.
Treatment of patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa.
Thromb Haemost, 80 (1998), pp. 352
[16.]
U. Martinowitz, G. Kenet, E. Segal, J. Luboshitz, A. Lubetsky, J. Ingerslev, et al.
Recombinat activated factor VII for adjunctive haemorrhage control in trauma.
J Trauma Inj Inf Crit Care, 51 (2001), pp. 431-439
[17.]
U. Hedner.
Recombinant activated factor VII as a universal haemostatic agent.
Blood Coag Fibrinolysis, 9 (1998), pp. 147s-152s
[18.]
N. O'Connell, C. Mc Mahon, J. Smith, K. Khair, I. Hann, R. Liesner, et al.
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
Br J Haematol, 116 (2002), pp. 632-635
[19.]
A.D. Shapiro.
Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors.
Semin Thromb Hemost, 26 (2000), pp. 413-419
[20.]
B.R. Saxon, D. Shanks, C.B. Jory, V. Williams.
Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-novoseven) in a child with high titre inhibitors and a target joint.
Thromb Haemost, 86 (2001), pp. 1126-1127
[21.]
J.D. Tobias, K. Groeper, J.W. Berkenbosch.
Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in paediatric patients.
Southern Med J, 96 (2003), pp. 12-16
[22.]
W.Y. Wong, W.C. Huang, R. Miller, K. Mc Ginty, J.K. Whisnant.
Clinical efficacy and recovery levels of recombinant FIIa (NovoSeven) in the treatment of intracraneal haemorrhage in sever neonatal FVII deficiency.
Haemophilia, 6 (2000), pp. 50-54
[23.]
S. Culié.
Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocitopenic purpura.
Br J Haematol, 120 (2003), pp. 907-915
[24.]
A. Chuansumrit, C. Sangkapreecha, P. Hathirat.
Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa.
Thromb Haemost, 82 (1999), pp. 1778
[25.]
P. Mathew, S.M. Beetstra, C.D. Tatlock, K.M. Ventre, J.E. Jones, M. Schwartz, et al.
Successful use of rFVIIa (NovoSeven) and fibrin sealant (Tisseal) during dental work and tooth extraction in a pediatric patient with Glanzmann's thrombasthenia.
Blood, 96 (2000), pp. 67b
[26.]
T. Revesz, B. Arets, M. Bierings, C. Van den Best, E. Duval.
Recombinant factor VIIa in severe uremic bleeding.
Thromb Haemost, 80 (1998), pp. 353
[27.]
Tobías JD.
Synthetic factor VIIa concentrates to treat coagulopathy and gastrointestinal bleeding in an infant end-stage liver disease.
Clinical Pediatrics, 41 (2002), pp. 613-616
[28.]
J.F. Lucía, E. Orna, C. Allepuz, C. Aguilar, M. Giralt, V. Carrasco, et al.
Successful outcome of a cirrhotic patient with postoperative hematuria treated with a high single dose of recombinant activated factor VII (rFVIIa).
Blood, 98 (2001), pp. 82b
[29.]
A. Chuansumrit, S. Treepongkaruna, P. Phuapradit.
Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases.
Thromb Haemost, 85 (2001), pp. 748-749
[30.]
G. Young, S. Lloyd, D.J. Nugent.
Recombinant factor VIIa in patients with liver failure undergoing surgery.
Blood, 96 (2000), pp. 267a
[31.]
A. Chuansumrit, T. Chantarojanasiri, P. Isarangkura, S. Teeraratkul, S. Hongeng, P. Hathirat.
Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
Blood Coagul Fibrinolysis, 11 (2000), pp. 101S-105S
[32.]
G. Young, D.J. Nugent.
Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant factor VIIa.
Hematology, 6 (2001), pp. 341-346
[33.]
M. Markiewicz, P. Kalicinski, A. Kaminski, H. Ismail, T. Drewniak.
Quick correction of hemostasis by recombinant activated factor VII as rescue therapy in pediatric surgery-our own experience.
Surg Childh Intern, 10 (2002), pp. 14-17
[34.]
J.D. Tobías.
Synthetic factor Vlla to treat dilutional coagulopathy during posterior spinal fusion in two children.
Anesthesiology, 96 (2003), pp. 1522
[35.]
M. Al Douri, T. Shafi, D. Al Khudairi, E. Al Bokhari, L. Black, N. Akinwale, et al.
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven [TM() in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.
Blood Coagul Fibrinolysis, 11 (2000), pp. 121S-127S
[36.]
Tobias JD.
Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant.
Pediatr Crit Care Med, 4 (2003), pp. 49-51
[37.]
W.H. Dzik, E.F. Grabowski, S. Feng, D. Ko, B. Cosimi, E.J. Israel, et al.
Preliminary experience with rFVIIa in children undergoing orthotopic liver transplantation.
Blood, 98 (2001), pp. 104b
[38.]
J.D. Morenski, J.D. Tobias, D.F. Jimenez.
Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. Report of three cases and review of the literature.
J Neurosurg, 98 (2003), pp. 611-616
[39.]
G. Greisen, R.B. Andreasen.
Recombinant factor VIIa in preterm neonates with prolonged prothrombin time.
Blood Coagul Fibrinolysis, 14 (2003), pp. 117-120
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados